A. O. Seidalin

A. O. Seidalin

Auto-generated profile, based on publicly available information

A. O. Seidalin

Kazakhstan-Russian Medical University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2024 in Innovative Medicine of Kuban
Verified
Journal Article
Open access
PDF file
BAB. A. Akbalaeva
B. A. Akbalaeva
LSL. V. Shulzhenko
L. V. Shulzhenko
IPI. V. Pershukov
I. V. Pershukov
NUN. Raiimbek Uulu
N. Raiimbek Uulu
TBT. A. Batyraliev
T. A. Batyraliev
MKM. R. Kamaliyeva
M. R. Kamaliyeva
Background: Cancer therapy-related cardiac dysfunction (CTRCD) is a new term that encompasses a wide range of potential manifestations and is etiologically associated with a wide variety of cancer treatments. Detection of early subclinical cardiac dysfunction is of great clinical importance.Objective: To assess subclinical CTRCD in women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab. We prospectively enrolled women aged 18-75 years with an established diagnosis of HER2-positive locally advanced or metastatic breast cancer across 3 centers.Material and methods: We monitored 122 women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab using speckle-tracking echocardiography. Based on the treatment protocol, we formed 3 comparison blocks: block 1 (chemotherapy: doxorubicin+cyclophosphamide); block 2 (chemotherapy+targeted therapy: docetaxel+trastuzumab), and block 3 (targeted therapy: trastuzumab).Results: The rate of subclinical CTRCD detection was high and exceeded 20%-30% in all comparison blocks after the 3rd course of chemotherapy, chemotherapy+targeted therapy, and targeted therapy. The rate of subclinical CTRCD increased significantly from the 1st to the 2nd, from the 2nd to the 3rd, from the 3rd to the 4th therapy courses in each block. Comparisons between the blocks were significant only after the 4th course of chemotherapy and the 4th course of targeted therapy (Yates-corrected chi-square, P=.0394); all the other comparisons between the blocks were not significant in terms of subclinical CTRCD rate.Discussion: Given the growing number of patients with breast cancer, such frequent monitoring of the cardiac function is likely to improve the quality of cancer treatment and might have a positive impact on the overall survival of patients with breast cancer. Conclusions: Criteria for frequency of echocardiographic monitoring of cardiac dysfunction in patients with malignant tumors, especially with HER2-positive breast cancer, should be revised.

10 June 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
IPI. V. Pershukov
I. V. Pershukov
BAB. A. Akbalaeva
B. A. Akbalaeva
LSL. V. Shulzhenko
L. V. Shulzhenko
TBT. A. Batyraliev
T. A. Batyraliev
OGO. V. Gurovich
O. V. Gurovich
NRN. N. Rakhalskaya
N. N. Rakhalskaya
Aim. To assess the incidence and timing of subclinical cardiac dysfunction associated with therapy for HER2-positive locally advanced or metastatic breast cancer, and to analyze the difference in time from significant reduction in left ventricular (LV) global longitudinal strain (GLS) to significant reduction in LV ejection fraction (LVEF) (cardiotoxicity "echo-loop").Material and methods. A total of 187 women 58±11 years without baseline cardiac dysfunction with verified HER2-positive locally advanced or metastatic breast cancer who received sequential adjuvant therapy with doxorubicin+cyclophosphamide, docetaxel+trastuzumab and trastuzumab monotherapy were followed up in 4 centers in four countries within 12 months with regular (every 3 weeks) speckle-tracking echocardiographic monitoring.Results. Subclinical cardiac dysfunction associated with breast cancer therapy (CTRCD) appears in each block of therapy after the first course. Its frequency increases significantly after each subsequent course compared to the previous one. By the end of the 4th course in each block of therapy, subclinical CTRCD is noted from 24,6% (almost every 4th patient in the chemotherapy block) to 32,6-33,7% (almost every 3rd patient in the chemotherapy and targeted therapy blocks). In 24 out of 25 cases of severe subclinical CTRCD (96%) with a fall in LVEF 15% was preceded. The time difference from a decrease in LV GLS to a decrease in LVEF <40% (cardiotoxicity "echo loop”) ranges from 5 to 16 weeks depending on the cancer therapy option.Conclusion. Until recently, the period of identified moderate subclini­cal cardiac dysfunction was not used to prescribe therapy for the pre­vention and treatment of cardiotoxicity. Enhanced speckle-tracking echo­cardiographic monitoring may reduce the incidence of severe sub­clinical and overt clinical cardiac dysfunction. Guidelines for car­diotoxicity monitoring should be reviewed to reduce the incidence of se­vere cardiac complications of cancer therapy.

26 December 2023 in Kardiologiia
Verified
Journal Article
Open access
PDF file
LSL. V. Shulzhenko
L. V. Shulzhenko
IPI. V. Pershukov
I. V. Pershukov
TBT. A. Batyraliev
T. A. Batyraliev
ZKZ. A. Karben
Z. A. Karben
OGO. V. Gurovich
O. V. Gurovich
EGE. V. Gaydukova
E. V. Gaydukova
Aim A 12-month evaluation of the potentialities of the angiotensin II receptor inhibitor olmesartan (Olme) and the angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan in patients with arterial hypertension (AH) and dyslipidemia in the dynamics of the following indicators of chronic heart failure (CHF): N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), LV global longitudinal strain (LV GLS) in diffuse myocardial fibrosis (MF) previously diagnosed by magnetic resonance imaging (MRI). Material and methods Olmesartan medoxomil (n=56) and sacubitril/valsartan (n=63) were used for 12 months in patients with hypertension, dyslipidemia and NYHA functional class II-III CHF with mid-range LVEF (CHFmrEF). MF was diagnosed by the following MRI criteria: late gadolinium enhancement and an increased proportion of extracellular matrix (33% or more). The frequency of persisting late gadolinium enhancement and the increased proportion of extracellular matrix (33% or more) was evaluated at 12 months; changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), NT-proBNP, and LV GLS were evaluated after 3, 6, and 12 months of follow-up. Results Baseline parameters did not differ between groups. The late gadolinium enhancement and increased proportion of extracellular matrix were present at baseline in all patients of both groups (100%; p=1.0). Already at 3 months, statistically significant decreases in SBP and DBP were observed in both groups. In addition, the LV GLS monitoring showed LV GLS significantly increased in both groups after 3 months and continued changing after 6 and 12 months. The NT-proBNP concentration significantly decreased in both groups already after 3 months and continued to decrease after 6 and 12 months. At 6 and 12 months, sacubitril/valsartan was superior to olmesartan in reducing SBP and NT-proBNP and in restoring LV GLS. At 12 months, the incidence of persisting, abnormal late gadolinium enhancement and increased proportion of extracellular matrix was significantly less in the ARNI group. Conclusion Olmesartan was demonstrated effective in the multi-modality therapy of CHFmrEF and MF in patients with AH and dyslipidemia. ARNI was superior to olmesartan in this regard, but further research of this issue is required.

30 October 2025 in Journal of Health Development
Verified
Journal Article
Open access
ВКВ.ж. Кудабаева
В.ж. Кудабаева
TTTimur Tastaibek
Timur Tastaibek
ННН.б. Насырова
Н.б. Насырова
АМА.т. Маншарипова
А.т. Маншарипова
АСА.о. Сейдалин
А.о. Сейдалин
The COVID-19 pandemic substantially altered the levels and structure of all-cause mortality: in addition to directlosses, indirect deaths arose due to health-system overload, delays in elective care, and changes in health-care seeking; seasonal profiles were disrupted, and the contribution of causes shifted—from infectious-respiratory to conditions whose outcomes depend on timely diagnosis and treatment. The aim of this study is to assess the impact of the COVID-19 pandemic on all-cause mortality in the Republic of Kazakhstan. We analyzed data on population counts and deaths by sex and 5-year age groups (1-4, …, ≥85) for 2015-2024; based on WHO data, periods were defined as pre-COVID (2015-2019), pandemic (2020-2023), and post-COVID (2024). Age-standardized mortality rates were calculated by the direct method using the 2013 European Standard Population (ESP 2013). Changes in levels and trends were assessed with a negative binomial model. Effects are presented as IRR (95% CI). The cause-of-deathstructure was compared using a year*cause contingency table (Pearson’s χ², Cramer’s V; standardized residuals;practical significance|r|>3). After a peak increase in standardized levels in 2020-2021, the indicators returned to the pre-COVID downward trajectory and fell below it: relative to 2019, age-standardized mortality increased by +19% in 2020 (2.113.6 vs 1.773.5 per 100.000) and by +33% in 2021 (2.358.0 per 100.000). In 2023-2024, age-standardized mortality declined to 1,504.5-1,493.7 per 100.000 (approximately 16% below 2019). Negative binomial regression showed no difference in the mean level for 2020-2023 versus pre-COVID (IRR=1.017; p=0.690) alongside an additional downward slope in the pandemic years (period*year interaction: IRR=0.960; 95% CI 0.931-0.991; p=0.012); in 2024 the level was substantially lower than pre-COVID (IRR=0.755; 95% CI 0.692-0.823). The cause-of-death structure exhibited a marked shift during the pandemic with partial normalization in 2022-2024. The pandemic had a short-term but pronounced effect on all-cause mortality, disrupting seasonal patterns and altering the cause-of-death structure while preserving age- and sex-related heterogeneity. Regular monitoring of all-cause and excess mortality should be maintained, causeof-death coding improved, and preventive and rehabilitation measures targeted to high-risk groups, taking into account possible delayed effects.